New injection shows promise for Hard-to-Treat lymphoma
NCT ID NCT07260812
First seen Jan 04, 2026 · Last updated May 13, 2026 · Updated 15 times
Summary
This early-stage study tests a new drug called KSV01 in 18 adults with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The main goal is to check safety and find the right dose. Researchers will monitor side effects and look for signs that the treatment is working.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
RECRUITINGWuhan, Hubei, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.